Chen Min-Li, Liao Ning, Zhao Hua, Huang Jian, Xie Zheng-Fu
Department of Geriatrics and Gerontology, First Affiliated Hospital, Guangxi Medical University , Nanning , China .
Immunol Invest. 2014;43(4):337-48. doi: 10.3109/08820139.2013.879170. Epub 2014 Feb 24.
Previous studies have provided conflicting evidence implicating the IL-13 C-1112T and G2044A polymorphisms in Graves' disease (GD) risk. We undertook a meta-analysis to address this issue.
The Medline, Pubmed and Web of Science databases were searched for published case-control studies investigating the relation of the IL-13 C-1112T and G2044A polymorphisms with GD risk. Data were extracted using standardized forms and odds ratios (OR) with 95% confidence intervals (CI) were calculated.
Available data did not suggest an association between any of the two IL-13 polymorphisms and GD risk. For the C-1112T polymorphism, the combined OR was 0.96 (95% CI: 0.77-1.19) for dominant model (TT+CT vs CC), 0.97 (95% CI: 0.69-1.38) for recessive model (TT vs CT+CC), and 0.97 (95% CI: 0.68-1.39) for homozygote model (TT vs CC). ORs for the G2044A polymorphism were similar. In subgroup analyses stratified by ethnicity, we also did not find associations between these two variants and GD risk in Asians or Caucasians. Sensitivity analyses by excluding each of the involved study in turn did not change the pooled results.
The IL-13 C-1112T and G2044A polymorphisms are not associated with GD risk.
既往研究提供了相互矛盾的证据，表明白细胞介素-13（IL-13）基因C-1112T和G2044A多态性与格雷夫斯病（GD）风险有关。我们进行了一项荟萃分析以解决这一问题。
检索Medline、Pubmed和科学网数据库，查找已发表的病例对照研究，探讨IL-13基因C-1112T和G2044A多态性与GD风险的关系。使用标准化表格提取数据，并计算比值比（OR）及95%置信区间（CI）。
现有数据未提示两种IL-13多态性中的任何一种与GD风险存在关联。对于C-1112T多态性，显性模型（TT + CT vs CC）的合并OR为0.96（95% CI：0.77 - 1.19），隐性模型（TT vs CT + CC）为0.97（95% CI：0.69 - 1.38），纯合子模型（TT vs CC）为0.97（95% CI：0.68 - 1.39）。G2044A多态性的OR值相似。在按种族分层的亚组分析中，我们也未发现这两种变异与亚洲人或高加索人中的GD风险存在关联。依次排除每项纳入研究的敏感性分析未改变汇总结果。
IL-13基因C-1112T和G2044A多态性与GD风险无关。
